{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:40:30Z","timestamp":1785404430254,"version":"3.56.0"},"reference-count":41,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University  of  Medicine  and  Pharmacy  of Craiova"},{"id":[{"id":"https:\/\/ror.org\/031d5vw30","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objective: Psoriasis is a systemic inflammatory disease often associated with metabolic comorbidities, including hyperuricemia. While biological therapies effectively target inflammatory pathways, their specific impact on serum uric acid (SUA) levels remains debated. This study aimed to evaluate whether biological therapy, while reducing systemic inflammation, influences SUA levels in patients with moderate-to-severe plaque psoriasis. Methods: A prospective longitudinal cohort study was conducted involving 30 patients with moderate-to-severe plaque psoriasis. Patients received biological treatment (adalimumab, secukinumab or ustekinumab) and tsDMARDS (apremilast). Clinical severity was assessed using the Psoriasis Area and Severity Index (PASI). C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), SUA levels and other laboratory markers were measured at baseline and after 48 weeks of therapy. Results: Biological therapy led to a significant reduction in PASI scores (from 21.6 \u00b1 10.7 at baseline to 0.4 \u00b1 0.86 after 48 weeks of therapy, p &lt; 0.001), and CRP decreased from a median of 5.75 mg\/L at baseline to 3.55 mg\/L, p &lt; 0.001. ESR also declined from 26.2 \u00b1 11.4 mm\/h to 19.0 \u00b1 8.06 mm\/h, p &lt; 0.001. However, no statistically significant change was observed in mean SUA levels 5.49 \u00b1 1.55 vs. 5.55 \u00b1 1.60 mg\/dL; p = 0.758. Subgroup analysis revealed that SUA levels remained stable regardless of the specific biological agent used or the degree of clinical improvement. Conclusions: Our findings suggest that while biological therapy is highly effective in controlling skin and systemic inflammation in psoriasis, it does not modify SUA levels. These results imply that hyperuricemia in psoriasis may be driven by metabolic factors independent of the primary inflammatory pathways targeted by current biologics.<\/jats:p>","DOI":"10.3390\/jcm15103817","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:19:29Z","timestamp":1778854769000},"page":"3817","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biological Therapy Leads to a Reduction in Systemic Inflammation but Leaves Serum Uric Acid Unmodified in Moderate-to-Severe Plaque Psoriasis: A Prospective Longitudinal Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Larisa Ionela","family":"Suiu","sequence":"first","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentin Ananu","family":"Vreju","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-276X","authenticated-orcid":false,"given":"Adina","family":"Turcu-Stiolica","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Health Economics and Outcomes Research Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Victor Babes Street No. 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana Elena","family":"Stoica","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8086-9029","authenticated-orcid":false,"given":"Mihai","family":"Turcu-Stiolica","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Emergency County Clinical Hospital of Craiova, 1 Tabaci Street, 200642 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina Lucia","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, C.H., Wu, N.L., and Tsai, T.F. (2025). How cells die in psoriasis?. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202504.0267.v1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70090","DOI":"10.1111\/exd.70090","article-title":"Hyperuricemia exacerbates psoriatic inflammation by inducing M1 macrophage activation and Th1 cell differentiation","volume":"34","author":"Wei","year":"2025","journal-title":"Exp. Dermatol."},{"key":"ref_3","first-page":"671","article-title":"Associations between psoriasis, psoriatic arthritis and gout or hyperuricemia: A systematic review and meta-analysis","volume":"369","author":"Liu","year":"2025","journal-title":"Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Huang, Y.H., See, L.C., Chang, Y.C., Chung, W.H., Chang, L.C., Yang, S.F., and Su, S.C. (2021). Impact of ABCG2 gene polymorphism on the predisposition to psoriasis. Genes, 12.","DOI":"10.3390\/genes12101601"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00403-025-03882-z","article-title":"Association between serum uric acid levels and arterial stiffness in patients with psoriasis","volume":"317","author":"Li","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_6","first-page":"934","article-title":"Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis","volume":"57","author":"Liu","year":"2025","journal-title":"J. Peking Univ. (Health Sci.)"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PTT.S486152","article-title":"Impact of IL-17A inhibitors on serum uric acid levels in psoriatic patients with hyperuricemia: A prospective observational study","volume":"14","author":"Wu","year":"2024","journal-title":"Psoriasis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2147\/CCID.S351984","article-title":"Serum intestinal metabolites are raised in patients with psoriasis and metabolic syndrome","volume":"15","author":"Sun","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/CCID.S411636","article-title":"A comparison of clinical characteristics in overweight\/obese and normal weight patients with psoriasis vulgaris: A bicentric retrospective observational study","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/CM9.0000000000002130","article-title":"Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.abd.2024.09.010","article-title":"Latin American consensus on psoriasis severity classification","volume":"100","author":"Castillo","year":"2025","journal-title":"An. Bras. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical Power Analyses Using G*Power 3.1: Tests for Correlation and Regression Analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5114\/ada.2024.139123","article-title":"A retrospective analysis of comorbidities in patients with psoriasis at a single centre","volume":"41","author":"Huang","year":"2024","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hu, M., Wang, Y., Xu, W., Bai, J., and Tang, X. (2024). The impact of serum uric acid on psoriasis: NHANES 2005\u20132014 and Mendelian randomization. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1334781"},{"key":"ref_15","first-page":"77","article-title":"Metabolic syndrome prevalence in psoriasis patients","volume":"67","author":"Marculescu","year":"2022","journal-title":"Dermatovenerol. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, L., Sun, X., Li, H., Wang, Y., Zhou, M., Hua, L., Li, B., and Li, X. (2021). Updated evidence of the association between elevated serum uric acid level and psoriasis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.645550"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Han, R., Hou, J., Xia, P., Xing, Y., and Liu, W. (2025). Predicting abnormal epicardial adipose tissue in psoriasis patients by integrating radiomics from non-contrast chest CT with serological biomarkers. BMC Med. Imaging, 25.","DOI":"10.1186\/s12880-025-01755-5"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e038882","DOI":"10.1161\/JAHA.124.038882","article-title":"Catheter ablation of atrial fibrillation in patients with psoriasis: A multicenter study","volume":"14","author":"Compagnucci","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1007\/s10753-025-02303-7","article-title":"From homeostasis to inflammation to autoimmunity: The potential impact of CRP","volume":"48","author":"Ahmed","year":"2025","journal-title":"Inflammation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5114\/ada.2023.135605","article-title":"Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris","volume":"41","author":"Chen","year":"2024","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s10067-025-07400-4","article-title":"Hyperuricemia in psoriatic arthritis: Clinical correlations and implications","volume":"44","author":"Tabra","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hagino, T., Saeki, H., Fujimoto, E., and Kanda, N. (2023). Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051934"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/1756-185X.13265","article-title":"Hyperuricemia in Asian psoriatic arthritis patients","volume":"21","author":"Lai","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1590\/abd1806-4841.20187547","article-title":"Serum uric acid levels and hyperuricemia in patients with psoriasis: A hospital-based cross-sectional study","volume":"93","author":"Gui","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5114\/reum.2022.119043","article-title":"Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis","volume":"60","author":"Olszewski","year":"2022","journal-title":"Reumatologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CCID.S509739","article-title":"Comorbidity pattern in patients with moderate-to-severe plaque psoriasis: Network analysis of a hospitalized database in China","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"26332","DOI":"10.1038\/s41598-024-77222-y","article-title":"Evaluating causal influence of serum uric acid on psoriasis via observational study and transethnic Mendelian randomization analyses","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_28","first-page":"37","article-title":"The role of uric acid in metabolic syndrome in patients with psoriasis","volume":"51","year":"2017","journal-title":"Turk. Arch. Dermatol. Venereol."},{"key":"ref_29","first-page":"437","article-title":"Hyperuricemia in psoriasis and psoriatic arthritis","volume":"13","author":"Mohammed","year":"2022","journal-title":"Ann. Clin. Anal. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e15103","DOI":"10.1111\/exd.15103","article-title":"Exploration of circulating metabolic signature of erythrodermic psoriasis based on LC-MS metabolomics","volume":"33","author":"Guo","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tripolino, C., Ciaffi, J., Ruscitti, P., Giacomelli, R., Meliconi, R., and Ursini, F. (2021). Hyperuricemia in psoriatic arthritis: Epidemiology, pathophysiology, and clinical implications. Front. Med., 8.","DOI":"10.3389\/fmed.2021.737573"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: A comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, L., Wang, Y., Qiu, L., and Wu, J. (2022). Psoriasis and cardiovascular disease risk in European and East Asian populations: Evidence from meta-analysis and Mendelian randomization analysis. BMC Med., 20.","DOI":"10.1186\/s12916-022-02617-5"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.abd.2024.07.013","article-title":"Psoriasis and cardiovascular risk: Associated and protective factors","volume":"100","author":"Agoglia","year":"2025","journal-title":"An. Bras. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, L., Cui, S., Liu, M., Huo, X., Zhang, G., and Wang, N. (2022). Psoriasis increased the risk of adverse cardiovascular outcomes: A new systematic review and meta-analysis of cohort studies. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.829709"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/jamacardio.2024.2859","article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis","volume":"9","author":"Ramessur","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Terui, H., and Asano, Y. (2023). Biologics for reducing cardiovascular risk in psoriasis patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031162"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lin, T.L., Fan, Y.H., Fan, K.S., Juan, C.K., Chen, Y.J., and Wu, C.Y. (2025). Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004591"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/cj.98254","article-title":"Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update","volume":"31","author":"Borghi","year":"2024","journal-title":"Cardiol. J."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Al-Azem, F., Schrader, B., Schrader, J., Els\u00e4sser, A., Vaske, B., and L\u00fcders, S. (2025). Hyperuricemia as an early indicator of cardiovascular risk in the general population. J. Clin. Med., 14.","DOI":"10.20944\/preprints202510.0460.v1"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chen, F., Yuan, L., Xu, T., Liu, J., and Han, S. (2022). Association of hyperuricemia with 10-year atherosclerotic cardiovascular disease risk among Chinese adults and elders. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19116713"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3817\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:34:50Z","timestamp":1778855690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103817"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103817","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}